Peptides made in the USA

What peptides made in the USA can mean

Peptides made in the USA resolves into four stages, and they come apart cleanly. Synthesis is where the chain is actually built, almost always by solid-phase peptide synthesis in a facility with the equipment and the chemists to do it. Analytical testing is where peptide purity and identity are measured. Packing is where material goes into labelled vials. Shipping is where the parcel leaves from.

Each of these can sit in a different country, and in this category they routinely do. A vial can be synthesised in one country, shipped in bulk, tested by a laboratory in one US state, filled and labelled in another, and dispatched from a third. Every one of those last three steps is domestic while the molecule itself was not made here.

None of that is improper. It is how most of the global peptide supply chain works, including for material that ends up in pharmaceutical use. What is improper is describing the whole chain by its last link.

The four stages separate because their costs are nothing like each other. Building a forty-residue chain by solid-phase synthesis needs a plant, resin, protected amino acids, purification columns and chemists who have done it before; filling vials needs a clean room and a filling line; dispatching a parcel needs a warehouse and a label printer. A seller can own the last two outright and have no relationship at all with the first: not even a contract, just a purchase order to a broker.

So the useful question is never "is this American?" It is "which stage are you describing, and what will you put in writing?" The table below is that question in reference form: every wording in common use, the stage it actually describes, and the thing a buyer can ask for to test it.

What the FTC standard requires of peptides made in the USA

The Federal Trade Commission holds unqualified "Made in USA" claims to a demanding line: the product must be all or virtually all made in the United States, meaning that final assembly happens here and that all or virtually all of the significant inputs and processing are domestic too.

For a peptide, the significant input is the peptide. If the chain was synthesised outside the US, an unqualified claim is not available, and what the seller has is a qualified claim instead. "Assayed in the USA", "packed in the USA" and "ships from the USA" are each perfectly respectable when stated as themselves.

Since August 2021 this has not only been policy. The Made in USA Labeling Rule, 16 CFR Part 323, puts the all-or-virtually-all standard into a rule the Commission can enforce directly with civil penalties, and it reaches labels, mail-order catalogues and online advertising alike, which is to say the product page and the homepage banner, not just the sticker on the box.

Qualified claims are the pressure valve, and they are permitted when they are truthful and the qualification is clear and conspicuous rather than buried. "Assembled in USA", "Filled in the USA" and "Tested in the USA" are all available to a seller willing to say what actually happened. The problem with peptides made in the USA as a category is not that sellers cannot describe their chain accurately. It is that describing it accurately is less impressive than a flag.

One more distinction worth holding onto: this is a labelling standard, not a quality standard. Where a chain was synthesised does not by itself make material purer or worse. What decides quality is whether the specific lot was measured and by whom, which is a question about documents rather than geography.

Who really manufactures peptides made in the USA

There is a real answer to this, and it is worth knowing because it reframes the whole question. The United States does host serious peptide manufacturing capacity. It is just almost entirely business-to-business, and almost none of it sells vials to researchers.

The names behind genuine peptides made in the USA are a short list. AmbioPharm runs peptide API manufacture at North Augusta, South Carolina, at multi-kilogram scale and publishes its FDA inspection history. Bachem, a Swiss company, operates US sites at Torrance and Vista in California. CordenPharma has a peptide plant at Boulder, Colorado, and PolyPeptide Group one at Torrance. Phoenix Pharmaceuticals in California has supplied catalogue and custom peptides to research laboratories for decades. Biosynth states US sites at Gardner, Massachusetts and Louisville, Kentucky.

Look at what those companies sell. Kilograms of active pharmaceutical ingredient, custom syntheses on contract, catalogue reagents against a purchase order and a quote. None of them is the entity behind a storefront selling 10mg vials with a research-use label, because the storefront is a different business: it buys bulk, has it filled, has it tested and sells it in units of one.

That is not a criticism, and it is not hidden. It is simply the structure of the market. But it means a research-peptide site claiming domestic manufacture is claiming a relationship with one of a small number of identifiable plants, and that is a claim which can be tested. Ask for the company and the city. Then check whether a facility of that name is registered with FDA as a drug establishment, which is a public register anyone can search. A named site that does not appear anywhere is a different kind of answer from no answer at all, and both are more informative than a flag.

The table below is the list, with what each company actually does. It is compiled from the companies' own published material, which is the appropriate standard of proof for corporate facts and the wrong standard of proof for anything in a vial.

cGMP, API-grade and research-grade are three different things

Every commercial page that ranks for this subject uses the letters GMP. Most research-vial buyers have no clear idea what they refer to, and the gap between the impression and the meaning is where a lot of this category's marketing lives.

cGMP, Current Good Manufacturing Practice, is a body of US regulation, 21 CFR Parts 210 and 211, governing how a drug is made, and FDA inspects facilities against it. It covers premises, equipment, records, personnel, change control and release. Note what it is not: it is not a test result, and it says nothing about the purity of any individual batch. A cGMP facility can make a batch that fails specification. The point of cGMP is that the failure is detected, documented and quarantined, not that it never happens.

API-grade sits just below that: material intended to be the active ingredient of a finished drug, made under cGMP and the ICH Q7 guideline. It is the grade the companies in the previous section actually sell.

Research-grade is the third thing, and it is the one in the vial. A research peptide is not a drug, not an API, and not a compounded preparation. No manufacturing regulation attaches to it, no agency inspects the operation that filled it, and the entire quality argument therefore rests on a single artefact: an analytical report on that specific lot, produced by somebody with no stake in selling it.

This is why a "cGMP" badge on a research-peptide storefront needs reading carefully. At best it describes a facility somewhere upstream, which may be true and may be relevant. It is not a statement about the vial, and it cannot be, because the vial is not a regulated product. A certificate for the lot is a statement about the vial. That is the whole difference.

The tests that actually separate one vial from another

If country of origin does not predict what is in a vial, something has to. It does, and it is a short, boring list of measurements with standard methods and published reference chapters. This is where a buyer's attention is worth more than it is anywhere on a map.

Purity is measured by reversed-phase HPLC, on our certificates at 214 nm. The number it produces is an area percentage: of everything the detector registered, that proportion was the target peptide. It does not see water, salts or counter-ions, which are real mass in the vial. That is why net peptide content is reported separately where a certificate covers it, and why a peptide purity figure alone is an incomplete description of a bottle.

Identity is a different measurement and needs saying separately, because most storefronts quote purity and never mention it. Purity tells you how much of the sample was one substance. Identity tells you whether that substance is the one on the label. It is established by mass spectrometry, LC-MS on 48 of our 51 certificates and MALDI on some others, by checking the measured mass against the theoretical mass of the sequence. A vial can be 99.9% pure and 100% the wrong molecule, and only the mass spectrum catches it.

Endotoxin is the third, measured by the Limulus Amebocyte Lysate assay against USP chapter <85>. It is a contamination measurement on the material, reported as a pass against a limit, ≤0.05 EU/mL where our certificates state one. It appears on 17 of the 51 certificates in our library, which is a figure worth publishing precisely because it is not all of them. Sterility, USP <71>, is a fourth test and a genuinely slow one: the compendial method incubates for 14 days, which is why a supplier advertising a same-week "sterility check" is describing something else.

The two laboratories whose reports we publish do not run the same panel. Freedom Diagnostics covers HPLC purity, identity by LC-MS on 48 of its 49 lots here, and on some lots LAL endotoxin. pH Solutions, which is ISO/IEC 17025 accredited, reports fill-weight conformance vial by vial and additionally covers microbials, mycotoxins, residual solvents and elemental impurities. Two labs, two panels, both published. That is the honest way to show it, and across 51 lots it gives a mean HPLC purity of 99.72%.

Why bulk peptide crosses a border at all

Sellers rarely explain this, and the explanation is unglamorous rather than sinister. Solid-phase peptide synthesis at scale is capital-heavy and skill-heavy, the plants that do it well are few, and a facility running kilograms is cheaper per gram than one running grams. The economics point at concentration, and concentration has happened: in the United States, in Switzerland, in India and in China. Bulk moves; vials do not.

What follows is a customs entry, and the mechanics are worth knowing because they are where "ships from the USA" is genuinely earned. Somebody has to be the importer of record: the party that files the entry with Customs and Border Protection, classifies the goods, pays any duty and is the one held responsible if the paperwork is wrong. A seller several steps downstream of that filing often does not know who it was. A seller who is the importer of record can say so in a sentence.

Once the bulk is domestic, the fill and finish that earns most domestic origin claims is ordinary work: material is weighed into vials, filled and dried as lyophilized powder, stoppered, capped and labelled with a lot number. Testing may happen before the fill, after it, or both. None of this is concealed in the industry. It is concealed only in the marketing.

The transit point is real and it is logistical rather than chemical. Material crossing a border can sit in customs for a stretch nobody can predict from the outside; a parcel selected for examination waits on the examination, not on a schedule. A research peptide that arrives a month late has failed regardless of its purity, and a diluent that arrives after the material it was bought to dissolve has failed at its one job. That is why bacteriostatic water, cheap and heavy and slow to clear, is the item most worth buying domestically.

Peptides made in the USA against the signals that are actually checkable

Two sensible reasons to ask where a peptide comes from, and one weak one.

The first is transit, covered above: domestic dispatch removes the border step entirely, which is a verifiable operational benefit.

The second is recourse. A research peptide supplier with a real address, domestic terms and a domestic warehouse is answerable in a way that an anonymous shipper is not. Again, this is about the business, not the molecule.

The weak reason is an assumption that peptides made in the USA means peptides that were tested. It does not. Plenty of material synthesised in the United States is sold with no certificate at all, and plenty synthesised elsewhere arrives with full independent peptide purity testing. Country of origin is not a proxy for testing, and treating it as one is how buyers end up with a flag on the website and no document in the box.

The table below is the whole argument of this article in one grid: every signal a seller can put in front of you, whether it is a measurement, who verifies it, and whether you can check it before you spend money. Only two rows survive all three tests, and neither of them is a country.

Price per milligram, and the arithmetic nobody publishes

Every storefront in this category prices per vial, and per vial is not a comparable unit. A 5mg vial at $49.99 and a 10mg vial at $79.99 are the same material at $10.00 and $8.00 per milligram, and the second is 20% cheaper by the only measure that describes the contents. The comparison takes one division and almost nobody does it, including, usually, the seller.

The habit is worth forming because it also defends against the opposite error. A cheaper vial is not a cheaper milligram, and a cheaper milligram of unassayed material is not cheap at all: if the purity figure is a claim rather than a document, the denominator is unknown and the arithmetic is meaningless. Price per milligram is only a fair comparison between two lots that both come with a certificate.

Our own catalogue, worked through: GHK-Cu is $39.99 for 50mg and $59.99 for 100mg, which is $0.80 and $0.60 per milligram. Ipamorelin is $49.99 for 5mg and $79.99 for 10mg, which is $10.00 against $8.00. Tesamorelin is $99.99 for 10mg and $189.99 for 20mg, $10.00 against $9.50, a narrower gap because the material is more expensive to make. BPC-157 ships in one size, 10mg at $59.99, which is $6.00 per milligram with the certificate for its current lot published against the number on the label.

Do the same division on any seller's page before comparing them to each other, and do it on the multi-vial sets too. The reference panels are priced as sets, so the per-milligram figure is the only way to see what the bundle is actually worth against the same vials bought singly. Then check that the figure you are dividing is attached to a lot certificate rather than to a marketing page. Two sellers quoting 99% purity, one with a signed report per lot and one without, are not selling the same thing at different prices. They are selling different things.

Ships from the USA: the numbers, published

"Ships from the USA" is the weakest of the four claims bundled inside peptides made in the USA, and it is also the only one of the four that can be reduced entirely to numbers. So here are ours, in one place, all of them stated on the shipping page rather than invented for an article.

Orders paid before 2pm ET on a business day are dispatched the same day; later orders and weekend orders go the next business day. Carriage is a flat $15 by FedEx 2Day and free over $250. Single vials ship in a padded mailer and larger orders in a small box, tracking is issued at dispatch, and damage is reportable for 72 hours from delivery with photographs of the packaging. Delivery is within the United States only for now, and every parcel leaves from the same US facility in Miami.

Lyophilised material is stable in transit, which is why it ships without cold packs. Storage once it arrives is the same wherever the material was made and has nothing to do with origin: the sealed vial at −20°C for long-term stability, 2 to 8°C for short-term handling, protected from light and not repeatedly frozen and thawed. How to store peptides goes through it properly.

None of this is a quality claim and none of it should be read as one. It is a set of commitments with numbers attached, which is the only kind of logistics statement worth reading, and the reason to publish them next to a discussion of origin is that they are what "ships from the USA" ought to mean.

What we can and cannot say about our own chain

What can be evidenced: every lot in this catalogue is assayed by an independent laboratory, and that laboratory, its method and the assay date appear on the certificate published against the lot number printed on the vial. Two laboratories have signed the 51 certificates we hold, one of them ISO/IEC 17025 accredited, and the reports are posted in full rather than summarised. Orders are warehoused and dispatched domestically, from Miami, with tracking on every parcel. Returns, terms and support are handled by a US business at a real address.

What is not claimed: a synthesis facility, and therefore not peptides made in the USA in the unqualified sense. No page on this site names a plant, a city or a company that built these chains, and that absence is deliberate, because naming one is the only way to make the claim checkable and an unnamed origin claim is precisely the thing this article exists to warn about. The product spec tables do carry a country-of-origin row reading United States; read against everything above, that describes the chain from which material is released, tested and dispatched, and it is not a statement that the peptide was synthesised here.

If that distinction costs us a sale against a competitor showing a flag, it is a reasonable price. The whole argument this business makes is that claims should be checkable, and a country-of-origin claim nobody can check would undercut the certificates that are the actual product.

There is a live reason to be careful as well as an editorial one. Through 2026 the FDA has been writing to sellers in this exact category, and what the letters cite is not country of origin at all. It is marketing: material described in terms of what it does in a person, dosing and administration guidance, disease references, and a research-use disclaimer at the foot of a page whose every other line addresses somebody who intends to use it. The agency's stated position is that it reads a site as a whole and infers intent from it. A seller who will overstate where a molecule was made is, on the evidence of those letters, rarely the seller being careful about the rest.